Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Invested Capital: 2019-2025

Historic Invested Capital for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $855.1 million.

  • Harmony Biosciences Holdings' Invested Capital rose 39.77% to $855.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $855.1 million, marking a year-over-year increase of 39.77%. This contributed to the annual value of $675.4 million for FY2024, which is 40.13% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Invested Capital stood at $855.1 million for Q3 2025, which was up 7.99% from $791.8 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Invested Capital high stood at $855.1 million for Q3 2025, and its period low was $154.0 million during Q3 2021.
  • Moreover, its 3-year median value for Invested Capital was $553.6 million (2024), whereas its average is $607.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first tumbled by 47.71% in 2021, then surged by 124.57% in 2022.
  • Over the past 5 years, Harmony Biosciences Holdings' Invested Capital (Quarterly) stood at $188.5 million in 2021, then spiked by 114.76% to $404.8 million in 2022, then rose by 19.06% to $482.0 million in 2023, then spiked by 40.13% to $675.4 million in 2024, then skyrocketed by 39.77% to $855.1 million in 2025.
  • Its Invested Capital was $855.1 million in Q3 2025, compared to $791.8 million in Q2 2025 and $738.0 million in Q1 2025.